ENTX vs XFOR: stock comparison and AI forecast
Entera Bio Ltd. (ENTX) and X4 Pharmaceuticals, Inc (XFOR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ENTX Entera Bio Ltd.
- Price
- $2.99 +118.2% · 6M
- Market Cap
- $518M
- P/E Ratio
- 9.1x
- Size
- small-cap
- AI Forecast
XFOR X4 Pharmaceuticals, Inc
- Price
- $3.18 -25.9% · 6M
- Market Cap
- $315M
- P/E Ratio
- 1.5x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ENTX is 1.6 times larger than XFOR by market capitalization ($518M against $315M).
- XFOR trades at 1.5 times trailing earnings, ENTX at 9.1 times.
- Over the last six months ENTX returned +118.2% and XFOR -25.9%.
- ENTX carries 1.68 times debt per unit of equity, against 0.67 times for XFOR.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ENTX | XFOR |
|---|---|---|
| Market Cap | $518M | $315M |
| P/E Ratio | 9.06x | 1.49x |
| P/B Ratio | 71.25x | 2.27x |
| EPS | $0.33 | $2.13 |
| Book Value/Share | $0.04 | $1.40 |
| Revenue/Share | $0.00 | $0.10 |
| FCF/Share | $-0.06 | – |
Profitability & Margins
| Metric | ENTX | XFOR |
|---|---|---|
| ROIC | -82.9% | -37.1% |
| Gross Margin | – | 88.0% |
| Operating Margin | – | -812.8% |
| EBT Margin | – | -810.9% |
| Tax Rate | – | -0.0% |
Financial Health
| Metric | ENTX | XFOR |
|---|---|---|
| Current Ratio | 8.98x | 13.22x |
| Quick Ratio | – | 13.21x |
| D/E Ratio | 1.68x | 0.67x |
| Financial Leverage | 2.68x | 1.67x |
| Interest Coverage | – | -2.9x |
| Working Capital | $17M | $183M |
Cash Flow
| Metric | ENTX | XFOR |
|---|---|---|
| Operating Cash Flow | -$11M | -$76M |
| Free Cash Flow | -$11M | – |
| Capital Spending | -$70K | – |
Operational Efficiency
| Metric | ENTX | XFOR |
|---|---|---|
| Asset Turnover | 0.00x | 0.04x |
| Receivables Turnover | – | 6.7x |
| Inventory Turnover | – | 12.1x |
| Fixed Assets Turnover | 0.0x | 173.5x |
| Days Sales Outstanding | – | 54 days |
| Days Inventory | – | 30 days |
| Payables Period | – | 577 days |
| Cash Conversion Cycle | – | -492 days |
Income Statement
| Metric | ENTX | XFOR |
|---|---|---|
| Total Revenue | $0.00M | $10M |
| Operating Income | -$14M | -$80M |
| R&D Expense | $9M | $62M |
| SG&A Expense | $550K | – |
| Cost of Goods Sold | $0.00M | $3M |
Dividend & Shareholder Information
| Metric | ENTX | XFOR |
|---|---|---|
| Shares Outstanding | 173M | 99M |
| EPS Growth | 32.0% | – |
ENTX vs XFOR: stock comparison and AI forecast
Which is bigger, ENTX or XFOR?
ENTX is 1.6 times larger than XFOR by market capitalization ($518M against $315M).
Which is cheaper on earnings, ENTX or XFOR?
XFOR trades at 1.5 times trailing earnings, ENTX at 9.1 times.
Which stock performed better over the last six months, ENTX or XFOR?
Over the last six months ENTX returned +118.2% and XFOR -25.9%.
Which one does Intratio's AI model rank higher, ENTX or XFOR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.